{
  "meta": {
    "title": "Pharmacology_Neet_2025",
    "url": "https://brainandscalpel.vercel.app/pharmacology-neet-2025-bfa8aabe.html",
    "scrapedAt": "2025-11-30T13:02:49.054Z"
  },
  "questions": [
    {
      "text": "1. The given image is that of cardiac action potential. In which phase does Amiodarone act?",
      "choices": [
        {
          "id": 1,
          "text": "Phase 1"
        },
        {
          "id": 2,
          "text": "Phase 2"
        },
        {
          "id": 3,
          "text": "Phase 3"
        },
        {
          "id": 4,
          "text": "Phase 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Amiodarone acts mainly on Phase 3 of the cardiac action potential, that is, the repolarisation phase. <br><br>Amiodarone is a class III antiarrhythmic drug that blocks voltage-gated potassium channels. It acts by prolonging the action potential duration and refractory period of cardiac cells, which is beneficial in managing tachyarrhythmias like ventricular tachycardia and fibrillation. It also has weak calcium channel blocking, sodium channel blocking, and adrenergic blocking actions.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/99ff597c76d14348863ca403153afbdcx1279x1244.JPEG\" alt=\"Explanation Image\"><br><br>Adverse effects of amiodarone are:<br><br>* Prolonged usage of amiodarone causes pulmonary fibrosis<br><br>* Bradycardia and QT prolongation<br><br>* Hyperthyroidism or hypothyroidism<br><br>* Corneal micro-deposits <br><br>The image below shows skin pigmentation in a patient due to prolonged amiodarone therapy.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7b7106cde89d473ba5a76b594f0cea80x720x872.JPEG\" alt=\"Explanation Image\"><br><br>Pearl PM0115: Anti-arrhythmic drugs<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Explanation Image\"><br><br><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs </strong></span></p>\n</td>\n<td>\n<p><span> </span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span> </span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span> </span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property </span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property </span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>β- blockers</span></td>\n<td><span>- </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers </span></td>\n<td><span>Prolonged </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/aa707ea3a6624fd49a580a5c4de41698.GIF"
      ],
      "explanation_images": []
    },
    {
      "text": "2. Benralizumab was given for the treatment of asthma in a patient. What does this drug act on?",
      "choices": [
        {
          "id": 1,
          "text": "IL-1"
        },
        {
          "id": 2,
          "text": "IL-4"
        },
        {
          "id": 3,
          "text": "IL-5"
        },
        {
          "id": 4,
          "text": "TNF-alpha"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Benralizumab binds to IL-5 receptor and blocks the action of IL-5.<br><br>Anti–IL-5 and anti–IL-5 receptor (IL-5Rα) blocking antibodies inhibit eosinophilic inflammation in asthmatic patients. Benralizumab binds to IL-5 receptor and causes apoptosis and rapid resolution of eosinophilic inflammation in the airways.<br><br>Other monoclonal antibodies, generally approved for asthma, which act against IL-5, are Mepolizumab and Reslizumab.<br><br>Other options:<br><br>Option A: Anakinra acts on IL-1 and is used in the treatment of Rheumatoid arthritis.<br><br>Option B: Dupilumab acts on IL-4, and it is effective in atopic dermatitis and asthma.<br><br>Option D: Adalimumab acts on TNF-alpha and can be used in the treatment of Rheumatoid arthritis, Crohn’s disease, plaque psoriasis, and psoriatic arthritis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "3. A 20-year-old female with heartburn and acid taste in mouth was diagnosed with GERD. Which of the drugs will facilitate with increased gastric emptying and increased Lower Esophageal Sphincter tone?",
      "choices": [
        {
          "id": 1,
          "text": "Omeprazole"
        },
        {
          "id": 2,
          "text": "Metoclopramide"
        },
        {
          "id": 3,
          "text": "Vonoprazan"
        },
        {
          "id": 4,
          "text": "Sodium alginate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Metoclopramide will facilitate increased gastric emptying and increased lower esophageal sphincter tone. <br><br>Metoclopramide is an antiemetic that leads to coordinated contractions that enhance transit and is a first-line therapy in patients with gastroparesis. The effects are more prominently seen in the upper digestive tract, where it increases lower esophageal sphincter tone (LES) and also stimulates antral and small intestinal contractions. <br><br>It has the following pharmacological actions:<br><br>* Dopamine receptor antagonist <br><br>* Serotonin (5HT4) receptor agonist <br><br>* Serotonin (5HT3) antagonist<br><br>* Sensitisation of muscarinic receptors on smooth muscle.<br><br>The adverse effects of metoclopramide are primarily extrapyramidal effects, including acute dystonia, Parkinson-like symptoms (tremors, bradykinesia, rigidity), tardive dyskinesia, galactorrhea due to hyperprolactinemia, and methemoglobinemia in neonates.<br><br>Other options:<br><br>Option A: Omeprazole is a proton-pump inhibitor that causes suppression of gastric acid secretion without blocking any transmitter receptor.<br><br>Option C: Vonoprazan is a potassium-competitive acid blocker for the treatment of gastroduodenal ulcers.<br><br>Option D: Sodium alginate increases the viscosity of gastric contents, forms a thick frothy layer that floats on them like a raft and prevents contact of acid with the esophageal mucosa. It does not affect LES tone.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "4. An elderly male patient presents with fatigue and pallor. After further examination, he is found to have anaemia due to CKD. What will he likely benefit from?",
      "choices": [
        {
          "id": 1,
          "text": "Parenteral iron therapy"
        },
        {
          "id": 2,
          "text": "Darbepoetin alpha"
        },
        {
          "id": 3,
          "text": "Filgastrim"
        },
        {
          "id": 4,
          "text": "Folic acid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The patient with anaemia due to CKD will likely benefit from Darbepoetin alpha.<br><br>Anaemia in patients with chronic kidney disease (CKD) is primarily due to decreased erythropoietin production. Anaemia associated with CKD is treated with erythropoietin-stimulating agents (ESAs) such as darbepoetin and epoetin. Darbepoetin alfa is approved for use in patients who are anaemic secondary to CKD. It is longer-acting than epoetin and hence needs to be injected once a week, and is more convenient.<br><br>It can lead to a sudden increase in haematocrit, blood viscosity and peripheral vascular resistance. These can lead to hypertensive episodes, serious thromboembolic events, and occasionally seizures. <br><br>Other options:<br><br>Option A: Parenteral iron therapy can be used in conjunction with darbepoetin for the treatment of anaemia due to CKD, but it is not the primary choice.<br><br>Option C: Filgastrim is a granulocyte colony-stimulating factor and is used in chemotherapy-induced myelosuppression in non-myeloid malignancies.<br><br>Option D: Folic acid is used in the treatment of megaloblastic anaemia.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "5. Patient underwent chemotherapy and developed tumour lysis syndrome with elevated uric acid levels. He was treated with Pegloticase. What is the mechanism of action of Pegloticase?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of Xanthine oxidase"
        },
        {
          "id": 2,
          "text": "Hydrolysis of uric acid"
        },
        {
          "id": 3,
          "text": "Oxidation of uric acid"
        },
        {
          "id": 4,
          "text": "Inhibition of URAT1 in renal tubules"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The mechanism of action of pegloticase is the oxidation of uric acid.<br><br>Pegloticase catalyses the enzymatic oxidation of uric acid into allantoin, which is a more soluble inactive metabolite and can be easily eliminated by the kidney. The urate oxidase enzyme, which converts uric acid to allantoin, is absent in humans. <br><br>Pegloticase is a pegylated uricase (urate oxidase) used in the treatment of severe, refractory chronic gout or in cases where other urate-lowering therapies are contraindicated. The efficacy of this drug decreases if antibodies are produced against it, which occurs in many patients. This also increases the risk of infusion reactions. This requires monitoring of plasma uric acid levels, with rising levels as an indicator of antibody production.<br><br>Pegloticase can cause adverse reactions like vomiting, nausea, chest pain, constipation, diarrhoea, erythema, pruritus, urticaria, anaphylactic reactions and hemolysis in G6PD-deficient patients. It can also lead to flare-ups of gout during treatment.<br><br>Other options: <br><br>Option A: Febuxostat is a xanthine oxidase inhibitor approved for the treatment of hyperuricemia in patients with gout.<br><br>Option D: Probenecid inhibits the reabsorption of uric acid by acting on URAT-1 in renal tubules.<br><br>Pearl PM1929: Drugs precipitating Gout<br><br>Drugs that precipitate gout are-<br><br>Cyclosporine or cancer drugs\nAspirin (low dose)\nNiacin\nThiazide\nLasix (furosemide)\nEthambutol\nAlcohol\nPyrazinamide<br><br>Mnemonic for drugs precipitating gout is 'CANT LEAP'",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "6. A 40-year-old female was treated for long-term with hydrochlorothiazide for hypertension and developed renal stones. The mechanism of action responsible for this is:",
      "choices": [
        {
          "id": 1,
          "text": "Increased calcium excretion"
        },
        {
          "id": 2,
          "text": "Increased oxalate absorption"
        },
        {
          "id": 3,
          "text": "Decreased calcium excretion"
        },
        {
          "id": 4,
          "text": "Decreased citrate secretion"
        }
      ],
      "correct_choice_id": 4,
      "solution": "The mechanism of action responsible for this is decreased citrate secretion.<br><br>Urine citrate is a natural inhibitor of calcium-containing stones, and hence, lower urine citrate excretion increases the risk of stone formation. Alkalization of urine increases the excretion of citrate. However, Hydrochlorothiazide causes acidification of urine due to loss of hydrogen ions. This acidification of urine decreases the excretion of citrate. <br><br>Increased consumption of foods rich in alkali (i.e., fruits and vegetables) can increase urine citrate. For patients with lower urine citrate, the addition of supplemental alkali, like potassium citrate or bicarbonate, leads to an increase in urinary citrate excretion. <br><br>Other options:<br><br>Options A and C: Hydrochlorothiazide decreases urinary calcium excretion and hence prevents calcium-containing stones in the urine. It prevents the formation of calcium-containing renal stones by reducing calcium excretion.<br><br>Option B: Increased oxalate absorption leads to an increased risk of renal stones, but Hydrochlorothiazide doesn't affect oxalate absorption.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}